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1. Introduction
A central theme in our research programme is the search
for critical success factors for steering the innovative processes
in the rapidly developing international chains and networks.
We draw from various scientific fields, namely social network
theory, chain science, and industrial organisation theory;
and we combine these insight with the theories related to
the management of innovation. Up to now, the management
of innovation literature has focused only limited attention
at the chain and network level. The main focus has been
on the individual company and its interaction with the
external environment. The question is whether such a limited
view is still tenable. For all the companies hold that they are
part of networks of actors that influence each other. One
could argue, for example, that most of the fundamental
and applied research in the pharmaceutical industry takes
place within a network that includes biotechnological
companies and research institutions. Similarly, in other
business sectors it would be wrong to assume that innovation
takes place within one firm. A successful innovation entails
not only a new product, but the satisfaction of new demands
on quality, quantity, transparency with regard to the origin
of natural resources (the suppliers), timeliness (logistics
and distribution) and the availability of the product (e.g.
at the supermarket). Readers interested in knowing what
can go wrong if the cohesion of chain partners in the
innovation process is not optimal are encouraged to read
the example in the Harvard Business Review of May 2002
(Butman 2002). Therefore, innovation management at the
chain and network level is becoming increasingly important.
The article starts with a short introduction of innovation,
and innovative success, thereafter the framework for
innovation at the company level will be presented. After
defining the concepts of chains and networks, the given
framework will be applied at the chain and network level.
We then focus on the context, the chain and network
structure within which innovation has to take place, and
the market and technological developments that create the
opportunities for and the obstacles to innovation. Finally,
we will link these topics to our research programme.
2. Definition of innovation
First of all, what do we mean by innovation? In our research
programme we use the broad definition forwarded by the
well-known economist Schumpeter ([1912] 1934), who,
early in the 20th century, succinctly described innovation
as the creation of new combinations. These new
combinations can be a new product, a new technology for
an existing application, a new application of a technology,
the development or opening of new markets, or the
introduction of new organisational forms or strategies to
improve results. This means that an innovation can be not
only a new product, but a new production process, a far-
reaching re-organisation of production and distribution,
or even an improved way to achieve innovations, for example
by means of venture capitalism. That an important
innovation need not always be the result of a spectacular new
technology is demonstrated by the fact that it was a
distribution innovation, namely the introduction of the
container (Rosenberg 2001), that led to the greatest cost-
reduction in the transport sector. Innovation processes that
go beyond the individual company are also called
institutional or system innovations. The distinguishing
characteristic of system innovations is that they are complex,
because they involve many actors such as the business sector,
the government, non-governmental organisations, and of
course consumers, and they often require the balancing of
ecological, physical, spatial and socio-economic values.
This complexity makes it difficult to realise system changes
and makes it imperative that system innovations in particular
be managed with a system dynamic network approach. 
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3. Success of innovations
When can we call an innovation a success? On the surface,
this would seem quite simple. If the product is not a
commercial success, it has failed. However, in practice the
answer is more complex. A product may fail in financial
terms, but its development may have given a company
enough technical experience to make a subsequent
introduction very successful. For example, Viagra was
discovered when a number of the healthy male volunteers
in a clinical test complained about the side-effect of a
medicine they had been given for chest pain. As a medicine
for chest pain, Viagra failed; but as a medicine for the
treatment of erectile dysfunction it has become a great
success. This example also demonstrates another element
of innovation: the surprise discovery or serendipity, which
is so often important. Focusing on the agri-food sector, we
can see that here too there is a lack of clarity about what
constitutes success or failure. Approximately 700 to 750
new agri-food products are introduced annually in the
Netherlands, which means that each product is new in at
least one aspect, and that it is being introduced on a relatively
large market. Research results provided by Eilander (1997)
show that more than 80% of these product introductions
fail; while Stijnen et al. (2002) cite recent research indicating
that two-thirds of new products are still on the shelves one
year later, of which one-half can be considered a (possibly
great) success. For a meta-analysis of the concepts success
and failure and the success scores of innovations in various
studies, I refer to Hollander (2002). Our own research is
based on a multi-dimensional understanding of the concept
success, which includes financial as well as non-financial
parameters.
4. Critical success factors of innovation at
company level
In global research on the critical success factors of
innovation, I compared the best pharmaceutical companies
with those that are more average (Omta 1995). Based on this
comparison, I developed a framework of critical factors for
successful innovation, which cover the areas of strategy,
culture and innovation systems. 
First, the innovation strategy. Miles & Snow (1978) distinguish
the prospector and analyser strategies as the most important
offensive innovation strategies. Prospectors react
immediately to market opportunities and are often among
the first to introduce innovations on the market. Yet it is
not necessarily the prospectors who will become the market
leaders. Particularly with completely new products, the
advantages of being the ‘first-mover’ often turn out to be
illusory. After all, the prospector has to deal with higher
development and marketing costs, while other firms can
just copy the product and optimise it based on market
experiences. For completely new products, the firms that
are second or third to enter the market often become the
market leader (Hultink 1998 in Stijnen et al. 2002). It is
thus not unusual to see analyser firms develop the necessary
technology and then wait with it in order to react quickly
when a competitor introduces the new product. This means
that timing-to-market is of great strategic importance.
Second, a business culture directed towards innovation is
extremely important. While certainly capable of conducting
thorough and highly technical research, the somewhat
bureaucratic R&D departments of large concerns often lack
the flexibility and entrepreneurial drive that are so
characteristic of small companies. In my research I observed
that the more successful pharmaceutical concerns attempted
to recreate the entrepreneurial culture of small companies
within or as an extension of the larger concern. Greater
autonomy and responsibility were given to the project leader
and the R&D project team. In addition, there was an active
start-up and spinning-out policy. Many research employees
ended up in, often very successful, biotechnology companies
that were set up by or in cooperation with these large
pharmaceutical companies. A parallel development in other
industries was observed by my wife and me in a global
benchmarking study conducted in part in the US, where
more fundamental R&D is still kept at ‘arm’s length’. A
comparable development can be seen in the Netherlands,
exemplified by the recent transfer of KPN Telecom Research
to the Dutch knowledge institution, TNO.
The third critical factor is the innovation system. The more
successful pharmaceutical companies appeared to have a
stronger external orientation. They worked together closely
with biotechnology firms and knowledge centres, and their
employees spent a considerable amount of time attending
conferences, writing for publications and maintaining
contacts with external actors. In this way, firms run the risk
that employees will divulge company-sensitive information
during their presentations or in their informal discussions
with colleagues. The reality of this risk was demonstrated
by Glaxo workers, who were able to develop Zantec, Glaxo’s
highly successful medicine for the treatment of stomach
ulcers, based on information divulged during a presentation
at the Technical College of Hatfield by Professor Black, an
employee of SmithKline & French, Glaxo’s competitor at
the time (Omta 1995). It can be considered a consolation
that the two firms have merged since then to become
GlaxoSmithKline. In the interviews it became apparent that
the average firms have concentrated more on secrecy and the
S.W.F. (Onno) Omta
74 Chain and network science (2002)
risk of allowing vital information to leak out; while the
better firms are apparently less worried about the negative
consequences, and place more emphasis on the advantages
of external contacts, namely exposure to new ideas and
prevention of the ‘Not invented here’ syndrome. In recent
years, the external orientation has increasingly become the
subject of research. Among other factors, this has resulted
in a plea for integration of consumer values at an early stage
in the development process, i.e. the consumer orientation.
Von Hippel (1988) emphasises in this regard the importance
of selecting the right consumers to serve as the ‘lead users’.
Using a random selection of consumers can at best lead
nowhere and at worst push the innovation process in the
wrong direction. The better firms also focused more attention
on cross-functional integration. More departments were
involved at crucial steps in the development process, which
offered the added advantage of making it possible to discuss
problems that could be expected later-on in an early stage
of development, e.g. concerning up-scaling and production.
More attention was also given to ICT communication. Du
Pont, for example, has created approximately 240
technology-related and 180 management-related ICT
information networks (Omta and Van Engelen 1998).
Finally, the human resource development systems were directed
more towards collective learning rather than emphasising
the success of individual projects. Staff exchanges between
departments and countries were encouraged on the basis of
special competency databases. Diverse career opportunities
were offered, in addition, and as an alternative, to the
dominant career path that leads to top management, ‘If you
want to get on, get out of research’.
5. Definition of chains and networks
Now that we have shed some light on the critical success
factors of innovation at firm level, we will introduce the
chain and network perspective from which we study
innovations. Within the framework of our research
programme, we define a network as follows: 
All of the actors within one industrial sector, or between related
industrial sectors, which can (potentially) cooperate to add value
for the consumer. 
We define actors at micro and meso level, for example the
individual farmer or consumer, or a company, research
institute or governmental department. Within this broadly
defined framework, a supply chain can be seen as a special
network, namely one in which the partners cooperate
vertically. 
Figure 1 shows a company as the focal point in a value chain
of suppliers and customers, which starts with the initial
producer, moves through a number of tiers of suppliers to
the focal company, and then proceeds through a number
of tiers of customers until it eventually reaches the end-
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Figure 1. Supply chain structure, source: Lambert and Cooper, 2000.
customer. Supply networks can vary in length and width. The
length of a network indicates the number of steps involved
between the initial producer and the end-customer, while
its width reflects the number of suppliers involved per step.
In recent years, the width of supply networks has generally
declined due to the movement towards a limited number
of ‘preferred suppliers’ (Van der Vorst 2000). The fact that
being a ‘preferred supplier’ is actually a mixed blessing was
demonstrated by the economising operation recently
announced by Opel (called ‘Olympia’) in which
expenditures to suppliers will be cut by 400 million euro.
6. Explanatory model for cooperation in
chains and networks
We see increasingly that firms no longer just set out on a
course towards innovation, but that they prefer to do so in
cooperation with others. Examples include co-innovation
of suppliers and customers, joint ventures and majority or
minority holdings of small start-up companies, particularly
in cooperation with knowledge centres. How do we apply
our framework for innovation, i.e. strategy, culture and
innovation systems, to these cooperative relationships at chain
and network level? For the top management it all starts with
the strategic choice between cooperation and integration, by
means of a merger or takeover. For example, if the
management of a pharmaceutical company decides to
cooperate with a biotechnology company in an early stage
of product development, then this decision was preceded
by the following strategic deliberation. If it were to take
over the biotechnology company, it would be buying a share
of the company knowing that the chance of receiving a very
positive return (that would not have to be shared with
others) is relatively small, while the chance is much greater
that the takeover would not be profitable at all. The ‘New
Chemical Entity’ may not progress beyond pre-clinical or
clinical research, or the present technology may not be
sufficient. However, if the pharmaceutical company waits
until there is more certainty, and, for example, the
biotechnology company has completed the most important
clinical research, with positive results, then the costs of a
takeover will have increased astronomically, or the revenue
will have to be shared with other firms. By entering into
cooperative relationships at an early stage with a number
of biotechnology companies, the management of the
pharmaceutical company reduces its uncertainty by
increasing its strategic flexibility (Volberda 1992). The
management thus buys a package of options, including
some that can be expected to fail and others that should
eventually perform well enough to greatly outweigh the
losses. The number of these options can be very high; on
average the largest 15 pharmaceutical companies participate
in 50 R&D alliances with biotechnology companies. It is
interesting to note that the size of these networks can vary
greatly from around 10 to more than 70 R&D alliances per
firm. A closer look reveals that these variations stem from
completely different strategic concepts held by the top
management of the pharmaceutical companies. Interesting
questions addressed in our research projects are: What are
these differences in strategy based on? And what can this
teach us about strategy development in innovation
networks?
If we concentrate on the cultural aspect, then we see that
trust plays an important role. A comparable culture, at
country or company level, contributes to a relationship
based at the outset on mutual trust between the partners.
Research conducted by Omta and Van Rossum (1999) on
the ‘dark side of cooperation’ revealed that it is these types
of cultural differences that often play an important role in
the failure of alliances. A good reputation in the network is
cited in the management literature as an essential ingredient
for initial trust and for the eventual success of a alliance.
However, research has shown that these types of assumptions
are in fact quite context-related. Bailey et al. (1996)
concluded on the basis of their research among 70 alliances
that it is not advisable to make a judgment based on previous
positive experience with a partner, because a new innovative
trajectory will often require different competencies and
know-how. Based on their research findings, they even
believe that selecting partners based on their good reputation
within a network only will doom the project to fail.
Omta and Van Rossum (1999) also concluded that in the
innovation management literature too little attention is
paid to the contractual aspect of cooperation. In a alliance
directed toward innovation, the uncertainty inherent in
cooperation is amplified. The advantages of opportunistic
behaviour can be relatively great, because unexpected, and
commercially very attractive, results might be achieved. This
is particularly true if a company does not know its partner
very well at the outset, which is generally the case in
cooperation between industrial sectors and in international
alliances. Finally, good innovation systems are possibly even
more important at chain and network level than for
innovation at the company level. For example, without
effective monitoring and a clear commitment from top
management, daily activities in one’s own laboratory will
quickly become more important than the interests of the
alliance. The research by Omta and Van Rossum also revealed
that research conducted in consortiums was more likely to
exceed deadlines, with the accompanying risk of losing
focus and incurring high additional costs. 
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7. The context: characteristics of the
market, technology, and chains and
networks
Now that I have given an overview of the characteristics of
cooperation, I would like to focus on the context: the
characteristics of the market and technology that provide
opportunities for and obstacles to innovation, and the
characteristics of chains and networks within which
innovation has to take shape. The characteristics of the
market and technology refer to turbulence, degree of
complexity, dynamics and unpredictability, which are all
influenced by the characteristics of the industry as identified
by Porter (1985), such as the level of entrance restrictions,
substitution opportunities and the level of competition.
According to Porter’s model, the most important factor at
chain level is the balance of power between suppliers and
buyers. Depending on the type of market and chain,
innovation can offer either the suppliers or the buyers greater
advantages. Based on research among 114 suppliers in the
auto industry, Kamath and Liker (1990) underlined the
importance of this dependence relationship. The most
dependent suppliers were prepared to invest (sometimes
large sums) in innovation if they knew that this investment
was desired by the customer, even if it was not profitable for
them from a purely economical perspective. 
Authors, like Burt (1992) and Uzzi (1997), formulate the
general mechanism by which relationships between firms
and the changes in networks can be explained. The
explanatory foundation upon which these theories are based
uses as a starting point two different aspects of networks,
namely the positioning of the firms in the structure of the
network and the nature of the mutual relationships. The
relevant aspects of the social embeddedness were already
noted above in relation to the characteristics of cooperative
relationships. The relevant point for our explanatory
problem is the degree to which the company has
opportunities within the structure of the network. Burt
formulates this as the positioning of the actors in a network
that enables them to span ‘structural holes’. For example, one
party can be in a strategic position for the implementation
of innovations if it is a partner in more than one tightly-
knit cluster of relationships such that it can serve as a bridge
by introducing innovations from one network into the
other. This leads to the paradoxical situation in which the
chance of achieving completely new innovations (the so-
called radical innovations) decreases as more and more
companies in the network establish mutual contractual
arrangements, which is particularly relevant in the formation
of chains. Links with other companies in the chain can be
so strong that they prevent a company from successfully
implementing an innovation, even if it is in a strategic
position to do so. Burt calls this over-embeddedness. Burt
(1992) also stresses the importance of the network’s
heterogeneity. Particularly in complex or turbulent markets
and technologies, it is important that the network is
sufficiently heterogeneous. As, according to Ashby’s (1956)
famous adage: ‘Only variety can destroy variety’. This aspect
of reducing insecurity by increasing heterogeneity was
demonstrated above by the ‘option strategy’ of cooperation
between the pharmaceutical and biotechnology companies. 
Figure 2 presents the three related elements of the model,
namely the context and cooperation characteristics and the
critical success factors for innovation at company level. This
model makes it possible to make predictions on the potential
success of innovations implemented in chains and networks.
The combination of the three elements implies that our
model is an extension of Burt’s model. It predicts the
behaviour of individual companies, given their context,
structural position and social imbeddedness in the network. 
In our research programme we study the consequences of
a given network approach, focusing on the analysis of factors
that create opportunities for or obstacles to inter-company
cooperation directed toward innovation. Our research is
designed around three related research themes: innovation
benchmarking and system dynamic analysis, agri-pharma
innovation and the consequences of internationalisation
for innovation in the diverse chains and networks. The
research theme innovation benchmarking and system
dynamic analysis is designed to obtain a clear understanding
of innovation in the various chains and networks. The two
other research themes focus specifically on situations in
which both the advantages of cooperation and the possible
problems that can occur are magnified, namely innovation
in agri-pharma alliances, in which the competencies of the
two industries have to be integrated, and innovation in
international cooperations.
8. Innovation benchmarking and system
dynamic analysis
The first part of this research theme involves innovation
benchmarking, that is, systematically identifying and
comparing the differences in the innovative capacity of
various chains in the agri-food sector, with the objective of
discovering the underlying causes of these differences. We
compare innovations implemented by one chain partner
with innovations that involved numerous chain partners,
based on their degrees of success and the underlying critical
success factors. Galizzi and Venturini (in Alfranca et al.
2002) indicate that much of the innovative strength of the
Innovation in chains and networks
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agri-food sector can be found in the co-innovation of
packaging. We investigate which actors have taken the ‘lead’
in this type of innovation: Is it the ‘channel captain’
(Venkatraman 1997) or have other firms taken over the role
of ‘innovation captain’? And what do these co-innovations
learn us about the innovative strength of the chains involved?
The benchmarking research is a longitudinal study
conducted at 4-year intervals, which will make it possible
to study cause and effect relationships. 
This innovation benchmarking research in various chains
provides the database we use for the system dynamic
analysis. We study how companies can best approach
innovation in their specific chains and networks. We begin
with an analysis of the innovative structure, the institutions,
networks and actors. All relevant stakeholders are identified,
i.e. the chain partners, competitors, consumers, non-
governmental organisations, knowledge centres and
governmental institutions; and the formal and informal
relationships between them are examined. Subsequently, a
so-called ‘values and interests map’ is created that indicates
which (potentially conflicting) values and interests play a
role. A system dynamic analysis is then carried out that
incorporates in the model the often non-linear relations, feed
forward and feedback loops, and (by means of ‘gaming’)
the subjective human assessments. Based on a sensitivity
analysis, a hierarchy of expected bottlenecks is drawn.
Unexpected consequences of the innovations are thereby
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Figure 2. Conceptual framework for the research of innovation in chains and networks.
often revealed, and the chain and network conditions under
which these consequences occur can then be identified.
This eventually leads to the design of those system conditions
under which the innovation has the most chance of
succeeding, together with an estimation of the risks, costs
and benefits and the necessary competencies, means and best
alliance partners. 
9. Agri-pharma innovation
Burt’s assumption that innovation is most likely to occur
where ‘structural holes’ are bridged implies that there is a
good chance that innovations will occur where the domains
of various industries overlap. In our second research theme
we concentrate on the exciting new area that involves both
the agri-food and the pharmaceutical sectors, namely the
‘functional foods’ segment. A whole assortment of
‘functional food’ products is now being developed in the
spectrum between ‘food’ and ‘medicine’. That the two
industries meet in this new terrain was demonstrated by
the fact that both the Finnish firm Raico, a subsidiary of
the large pharmaceutical firm Johnson & Johnson, and the
food multinational Unilever introduced a new margarine
onto the market, under the brand names Benecol and Becel
ProActive, claiming that it reduces the level of LDL
cholesterol in the blood. We currently have three projects
that are studying the biotechnological developments,
particularly genomics and proteonomics (Baltimore 2001),
of ‘functional foods’. 
10. Internationalisation
That the internationalisation of business activities is not a
simple task was shown in recent research by Rugman (2001),
which indicates that the globalisation of multinational
enterprises has progressed only marginally. Most of these
multinational companies appear to concentrate mainly on
their own regions, which Rugman broadly defines as the
EU, NAFTA and Japan. Interestingly, it is the companies
within the life sciences industries that form the exception
to this rule. Food processing companies such as Unilever and
Nestlé and pharmaceutical companies such as Bayer,
GlaxoSmithKline and Novartis operate literally around the
globe. Of course it is not so surprising that food companies
operate globally. It is now possible to ship fresh food
products around the world and sell them fresh throughout
the year for a reasonable price. The large agri-food companies
are participating more and more in international networks,
which enable them to make optimum use of the
opportunities that various regions can offer. However, most
multinational companies have not been very good at
managing their international activities. Profit margins
outside of their own regions are considerably lower, and
they are not capable of anticipating changes in local
conditions. Ahold, for example, has pulled out of China
and reduced its activities in the rest of Asia, not to mention
its predicament caused by the recent crisis in Argentina.
Many other examples could also be cited, such as the
problems experienced by Numico, with its recent takeovers
in the USA of GNC and Rexall Sundown. Surely Numico
must have underestimated the American mentality and
readiness to ‘sue the bastards’. As noted earlier, international
alliances often fail, in part due to overwhelming cultural
differences. One of our research projects is aimed at
structurally identifying these cultural differences in order to
offer the business community an instrument with which
they can gauge their plans for international cooperation. 
It is our ambition to become an internationally recognised
knowledge centre on innovation in chains and networks. We
therefore invite research groups in other countries to join
us, so that we can work together towards achieving this
goal.
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